{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:09:26Z","timestamp":1789038566266,"version":"build-2803163510"},"reference-count":95,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Whether lower testosterone concentrations in aging men predispose to poorer health, particularly cardiovascular disease (CVD), remains controversial. This narrative review summarizes the relationships between testosterone and cardiovascular health outcomes, based on observational and interventional studies. Cross-sectional analyses show that lower endogenous testosterone concentrations are found in men with preexisting CVD, but larger influences are age &amp;gt;\u202f70 years, higher body mass index, and medical comorbidities such as diabetes or cancer. In the United Kingdom Biobank, the largest prospective cohort study to date, lower endogenous testosterone concentrations were associated with higher risk of all-cause mortality, but not incident cardiovascular events or CVD deaths. In an individual participant data meta-analysis of prospective cohort studies with testosterone measured using mass spectrometry, there were nonlinear associations of baseline testosterone concentrations with higher all-cause and cardiovascular mortality, with these risks increasing below thresholds of testosterone &amp;lt;\u202f7.4 nmol\/L (213 ng\/dL) and &amp;lt;\u202f5.3 nmol\/L (153 ng\/dL), respectively. In the randomized, placebo-controlled T4DM trial involving men with dysglycemia, testosterone treatment on a background of lifestyle intervention reduced risk of type 2 diabetes mellitus after 2 years. The TRAVERSE cardiovascular safety trial, conducted in men with CVD or multiple risk factors, found no increased risk of major adverse cardiovascular events in men randomized to testosterone treatment vs placebo, with average follow-up of 3 years. Based on epidemiological studies, and the results of T4DM and TRAVERSE, additional studies are needed to confirm long-term cardiovascular safety, and explore possible cardiovascular benefits related to changes in body composition and cardiometabolic risk.<\/jats:p>","DOI":"10.1210\/clinem\/dgaf622","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:06:18Z","timestamp":1762866378000},"page":"e339-e351","source":"Crossref","is-referenced-by-count":3,"title":["Endogenous Testosterone, Testosterone Treatment, and Cardiovascular Health Outcomes in Men"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7612-5892","authenticated-orcid":false,"given":"Bu B","family":"Yeap","sequence":"first","affiliation":[{"name":"Medical School, University of Western Australia , Perth, WA 6009 ,","place":["Australia"]},{"name":"Department of Endocrinology and Diabetes, Fiona Stanley Hospital , Perth, WA 6150 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley D","family":"Anawalt","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington School of Medicine , Seattle, WA 98195 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"2026012101523911300_dgaf622-B1","volume-title":"Endotext","author":"Handelsman","year":"2020"},{"issue":"6","key":"2026012101523911300_dgaf622-B2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1530\/EJE-15-0380","article-title":"Age-specific population centiles for androgen status in men","volume":"173","author":"Handelsman","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2026012101523911300_dgaf622-B3","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1210\/jc.2012-2265","article-title":"Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men","volume":"97","author":"Yeap","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026012101523911300_dgaf622-B4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5694\/mja16.00393","article-title":"Endocrine society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy","volume":"205","author":"Yeap","year":"2016","journal-title":"Med J Aust"},{"issue":"5","key":"2026012101523911300_dgaf622-B5","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026012101523911300_dgaf622-B6","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/alz.12529","article-title":"Lower serum testosterone concentrations are associated with a higher incidence of dementia in men: the UK biobank prospective cohort study","volume":"18","author":"Marriott","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"7","key":"2026012101523911300_dgaf622-B7","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1210\/clinem\/dgae703","article-title":"Associations of serum testosterone and sex hormone-binding globulin with incident fractures in middle-aged to older men","volume":"110","author":"Grahnemo","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026012101523911300_dgaf622-B8","doi-asserted-by":"crossref","first-page":"768","DOI":"10.7326\/M23-2781","article-title":"Associations of testosterone and related hormones with all-cause and cardiovascular mortality and incident cardiovascular disease in men: individual participant data meta-analyses","volume":"177","author":"Yeap","year":"2024","journal-title":"Ann Intern Med"},{"issue":"5","key":"2026012101523911300_dgaf622-B9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5694\/mja16.00448","article-title":"Endocrine society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations","volume":"205","author":"Yeap","year":"2016","journal-title":"Med J Aust"},{"issue":"10","key":"2026012101523911300_dgaf622-B10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2213-8587(24)00199-2","article-title":"Male hypogonadism: pathogenesis, diagnosis, and management","volume":"12","author":"De Silva","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2026012101523911300_dgaf622-B11","doi-asserted-by":"crossref","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"issue":"5","key":"2026012101523911300_dgaf622-B12","doi-asserted-by":"crossref","first-page":"e034777","DOI":"10.1136\/bmjopen-2019-034777","article-title":"Androgens in men study (AIMS): protocol for meta-analyses of individual participant data investigating associations of androgens with health outcomes in men","volume":"10","author":"Yeap","year":"2020","journal-title":"BMJ Open"},{"issue":"4","key":"2026012101523911300_dgaf622-B13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/dom.13601","article-title":"Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): design and implementation of a double-blind randomized controlled trial","volume":"21","author":"Wittert","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2026012101523911300_dgaf622-B14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ahj.2021.11.016","article-title":"Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study","volume":"245","author":"Bhasin","year":"2022","journal-title":"Am Heart J"},{"issue":"10486","key":"2026012101523911300_dgaf622-B15","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0140-6736(25)00055-8","article-title":"The Lancet commission on rethinking coronary artery disease: moving from ischaemia to atheroma","volume":"405","author":"Zaman","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"2026012101523911300_dgaf622-B16","doi-asserted-by":"crossref","first-page":"e1074\u2013","DOI":"10.1210\/clinem\/dgaa915","article-title":"Early decline of androgen levels in healthy adult men: an effect of aging per se? A prospective cohort study","volume":"106","author":"Banica","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026012101523911300_dgaf622-B17","doi-asserted-by":"crossref","first-page":"105851","DOI":"10.1016\/j.jsbmb.2021.105851","article-title":"Metabolism of testosterone during weight loss in men with obesity","volume":"209","author":"Van de Velde","year":"2021","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"2026012101523911300_dgaf622-B18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1530\/EJE-12-0890","article-title":"Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European male ageing study","volume":"168","author":"Camacho","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026012101523911300_dgaf622-B19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/cen.14342","article-title":"Sociodemographic, lifestyle and medical influences on serum testosterone and sex hormone-binding globulin in men from UK biobank","volume":"94","author":"Yeap","year":"2021","journal-title":"Clin Endocrinol"},{"issue":"2","key":"2026012101523911300_dgaf622-B20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.7326\/M21-0551","article-title":"Associations of serum testosterone and sex hormone-binding globulin with incident cardiovascular events in middle-aged to older men","volume":"175","author":"Yeap","year":"2022","journal-title":"Ann Intern Med"},{"issue":"2","key":"2026012101523911300_dgaf622-B21","doi-asserted-by":"crossref","first-page":"e625","DOI":"10.1210\/clinem\/dgaa743","article-title":"Serum testosterone is inversely and sex hormone-binding globulin is directly associated with all-cause mortality in men","volume":"106","author":"Yeap","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026012101523911300_dgaf622-B22","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.7326\/M23-0342","article-title":"Factors associated with circulating sex hormones in men. Individual participant data meta-analyses","volume":"176","author":"Marriott","year":"2023","journal-title":"Ann Intern Med"},{"issue":"9","key":"2026012101523911300_dgaf622-B23","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/aje\/kwx246","article-title":"Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population","volume":"186","author":"Fry","year":"2017","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2026012101523911300_dgaf622-B24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1530\/EJE-22-0104","article-title":"Higher premorbid serum testosterone predicts COVID-19-related mortality risk in men","volume":"187","author":"Yeap","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026012101523911300_dgaf622-B25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1210\/jc.2003-031287","article-title":"Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry","volume":"89","author":"Wang","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026012101523911300_dgaf622-B26","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.atherosclerosis.2007.05.009","article-title":"Endogenous testosterone and serum lipids in middle-aged men","volume":"197","author":"Makinen","year":"2008","journal-title":"Atherosclerosis"},{"issue":"1","key":"2026012101523911300_dgaf622-B27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.atherosclerosis.2012.02.020","article-title":"Relation of total and free testosterone and sex hormone-binding globulin with cardiovascular risk factors in men aged 24-45 years. The cardiovascular risk in young Finns study","volume":"222","author":"Firtser","year":"2012","journal-title":"Atherosclerosis"},{"issue":"1","key":"2026012101523911300_dgaf622-B28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/HJR.0b013e32833c1a8d","article-title":"Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia","volume":"18","author":"Haring","year":"2011","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2026012101523911300_dgaf622-B29","volume-title":"Endotext","author":"Yeap","year":"2022"},{"issue":"6","key":"2026012101523911300_dgaf622-B30","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s11154-022-09752-7","article-title":"Relationships between endogenous and exogenous testosterone and cardiovascular disease in men","volume":"23","author":"Thirumalai","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"2026012101523911300_dgaf622-B31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/978-3-031-31501-5_19","volume-title":"Testosterone: From Basic to Clinical Aspects. Second Edition","author":"Yeap","year":"2023"},{"issue":"1","key":"2026012101523911300_dgaf622-B32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1210\/jc.2015-2687","article-title":"Sex hormones and ischemic stroke: a prospective cohort study and meta-analyses","volume":"101","author":"Holmegard","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026012101523911300_dgaf622-B33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/cen.13089","article-title":"Neutral associations of testosterone, dihydrotestosterone and estradiol with fatal and non-fatal cardiovascular events, and mortality in men aged 17-97 years","volume":"85","author":"Chan","year":"2016","journal-title":"Clin Endocrinol"},{"issue":"11","key":"2026012101523911300_dgaf622-B34","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1161\/STROKEAHA.116.014088","article-title":"Association between endogenous testosterone and cerebrovascular disease in the ARIC study (atherosclerosis risk in communities)","volume":"47","author":"Srinath","year":"2016","journal-title":"Stroke"},{"issue":"8","key":"2026012101523911300_dgaf622-B35","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/2047487318819142","article-title":"Testosterone, sex hormone-binding globulin and risk of cardiovascular events: a report from the outcome reduction with an initial glargine intervention trial","volume":"26","author":"Wang","year":"2019","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"2026012101523911300_dgaf622-B36","doi-asserted-by":"crossref","first-page":"6301","DOI":"10.1210\/jc.2019-01317","article-title":"Higher serum sex hormone-binding globulin levels are associated with incident cardiovascular disease in men","volume":"104","author":"Gyawali","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026012101523911300_dgaf622-B37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/13685538.2018.1466876","article-title":"Endogenous testosterone does not improve prediction of incident cardiovascular disease in a community-based cohort of adult men: results from the Tehran lipid and glucose study","volume":"23","author":"Hatami","year":"2020","journal-title":"Aging Male"},{"issue":"10","key":"2026012101523911300_dgaf622-B38","doi-asserted-by":"crossref","first-page":"e3798\u2013","DOI":"10.1210\/clinem\/dgaa500","article-title":"Sex hormones and incident heart failure in men and postmenopausal women: the atherosclerosis risk in communities study","volume":"105","author":"Zhao","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026012101523911300_dgaf622-B39","doi-asserted-by":"crossref","first-page":"bvaa038","DOI":"10.1210\/jendso\/bvaa038","article-title":"Endogenous testosterone levels and the risk of cardiovascular events in elderly men: the MrOS prospective study","volume":"4","author":"Collett","year":"2020","journal-title":"J Endocr Soc"},{"key":"2026012101523911300_dgaf622-B40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ahj.2020.03.016","article-title":"Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease","volume":"224","author":"Boden","year":"2020","journal-title":"Am Heart J"},{"issue":"4","key":"2026012101523911300_dgaf622-B41","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/ehf2.13384","article-title":"Low testosterone concentrations and prediction of future heart failure in men and in women: evidence from the large FINRISK97 study","volume":"8","author":"Schafer","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"5","key":"2026012101523911300_dgaf622-B42","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1210\/jc.2016-1025","article-title":"Temporal changes in androgens and estrogens are associated with al-cause and cause-specific mortality in older men","volume":"101","author":"Hsu","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026012101523911300_dgaf622-B43","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/cen.13407","article-title":"Greater physical activity and higher androgen concentrations are independently associated with lower cardiometabolic risk in men","volume":"87","author":"Chasland","year":"2017","journal-title":"Clin Endocrinol"},{"issue":"1","key":"2026012101523911300_dgaf622-B44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1530\/EJE-17-0280","article-title":"Individual testosterone decline and future mortality risk in men","volume":"178","author":"Holmboe","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2026012101523911300_dgaf622-B45","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1210\/jc.2008-2416","article-title":"Lower testosterone levels predict incident stroke and transient ischaemic attack in older men","volume":"94","author":"Yeap","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026012101523911300_dgaf622-B46","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2014-2664","article-title":"In older men, higher plasma testosterone or dihydrotestosterone is an independent predictor for reduced incidence of stroke but not myocardial infarction","volume":"99","author":"Yeap","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026012101523911300_dgaf622-B47","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/ejendo\/lvad015","article-title":"Serum testosterone and sex hormone-binding globulin are inversely associated with leucocyte telomere length in men: a cross-sectional analysis of the UK biobank study","volume":"188","author":"Marriott","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026012101523911300_dgaf622-B48","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.amjcard.2015.11.063","article-title":"Impact of testosterone replacement therapy on myocardial infarction, stroke and death in men with low testosterone concentrations in an integrated health care system","volume":"117","author":"Anderson","year":"2016","journal-title":"Am J Cardiol"},{"issue":"6","key":"2026012101523911300_dgaf622-B49","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S2213-8587(16)00112-1","article-title":"Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study","volume":"4","author":"Wallis","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2026012101523911300_dgaf622-B50","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamainternmed.2016.9546","article-title":"Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency","volume":"177","author":"Cheetham","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"9","key":"2026012101523911300_dgaf622-B51","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.amjmed.2019.03.022","article-title":"Cardiovascular and cerebrovascular safety of testosterone replacement therapy among aging men with low testosterone levels: a cohort study","volume":"132","author":"Loo","year":"2019","journal-title":"Am J Med"},{"issue":"8","key":"2026012101523911300_dgaf622-B52","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.amjcard.2019.07.019","article-title":"Relation of testosterone normalization to mortality and myocardial infarction in men with previous myocardial infarction","volume":"124","author":"Oni","year":"2019","journal-title":"Am J Cardiol"},{"issue":"17","key":"2026012101523911300_dgaf622-B53","doi-asserted-by":"crossref","first-page":"e020562","DOI":"10.1161\/JAHA.120.020562","article-title":"Association between testosterone treatment and risk of incident cardiovascular events among US male veterans with low testosterone levels and multiple medical comorbidities","volume":"10","author":"Shores","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2026012101523911300_dgaf622-B54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.amjmed.2016.09.017","article-title":"Cardiovascular risks of exogenous testosterone use among men: a systematic review and meta-analysis","volume":"130","author":"Alexander","year":"2017","journal-title":"Am J Med"},{"issue":"11","key":"2026012101523911300_dgaf622-B55","doi-asserted-by":"crossref","first-page":"e015284","DOI":"10.1136\/bmjopen-2016-015284","article-title":"Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis","volume":"7","author":"Elliott","year":"2017","journal-title":"BMJ Open"},{"issue":"6","key":"2026012101523911300_dgaf622-B56","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jsxm.2018.04.641","article-title":"Testosterone and cardiovascular risk: meta-analysis of interventional studies","volume":"15","author":"Corona","year":"2018","journal-title":"J Sex Med"},{"issue":"2","key":"2026012101523911300_dgaf622-B57","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/M19-0830","article-title":"Efficacy and safety of testosterone treatment in men: an evidence report for a clinical practice guideline by the American college of physicians","volume":"172","author":"Diem","year":"2020","journal-title":"Ann Intern Med"},{"issue":"6","key":"2026012101523911300_dgaf622-B58","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2666-7568(22)00096-4","article-title":"Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis","volume":"3","author":"Hudson","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"7","key":"2026012101523911300_dgaf622-B59","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa1506119","article-title":"Effects of testosterone treatment in older men","volume":"374","author":"Snyder","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2026012101523911300_dgaf622-B60","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1210\/er.2017-00234","article-title":"Lessons from the testosterone trials","volume":"39","author":"Snyder","year":"2018","journal-title":"Endocr Rev"},{"issue":"4","key":"2026012101523911300_dgaf622-B61","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","article-title":"Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial","volume":"177","author":"Snyder","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"4","key":"2026012101523911300_dgaf622-B62","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamainternmed.2016.9540","article-title":"Association of testosterone levels with anemia in older men: a controlled clinical trial","volume":"177","author":"Roy","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"7","key":"2026012101523911300_dgaf622-B63","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jama.2016.21044","article-title":"Testosterone treatment and cognitive function in older men with low testosterone and age-associated memory impairment","volume":"317","author":"Resnick","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"2026012101523911300_dgaf622-B64","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.2016.21043","article-title":"Testosterone treatment and coronary artery plaque volume in older men with low testosterone","volume":"317","author":"Budoff","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"2026012101523911300_dgaf622-B65","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1210\/jc.2017-02243","article-title":"The effect of testosterone on cardiovascular biomarkers in the testosterone trials","volume":"103","author":"Mohler","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026012101523911300_dgaf622-B66","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S2213-8587(17)30416-3","article-title":"Testosterone treatment in older men: clinical implications and unresolved questions from the testosterone trials","volume":"6","author":"Yeap","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2026012101523911300_dgaf622-B67","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S2213-8587(20)30367-3","article-title":"Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial","volume":"9","author":"Wittert","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2026012101523911300_dgaf622-B68","doi-asserted-by":"crossref","first-page":"e3143","DOI":"10.1210\/clinem\/dgab149","article-title":"Effect of testosterone treatment on bone microarchitecture and bone mineral density in men: a 2-year RCT","volume":"106","author":"Ng Tang Fui","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026012101523911300_dgaf622-B69","doi-asserted-by":"crossref","first-page":"e2157","DOI":"10.1210\/clinem\/dgaf060","article-title":"Testosterone treatment and sexual function in men: secondary analysis of the T4DM (testosterone for diabetes) trial","volume":"110","author":"Wittert","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026012101523911300_dgaf622-B70","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1210\/clinem\/dgae085","article-title":"Testosterone treatment, weight loss, and health-related quality of life and psychosocial function in men: a 2-year randomized controlled trial","volume":"109","author":"Grossmann","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026012101523911300_dgaf622-B71","first-page":"613","article-title":"Mediation analysis of the testosterone treatment effect to prevent type 2 diabetes in the testosterone for prevention of type 2 diabetes Mellitus trial","volume":"188","author":"Robledo","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026012101523911300_dgaf622-B72","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1530\/EJE-21-0608","article-title":"Recovery of male reproductive endocrine function after ceasing prolonged testosterone undecanoate injections","volume":"186","author":"Handelsman","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026012101523911300_dgaf622-B73","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ejendo\/lvae166","article-title":"Predicting type 2 diabetes and testosterone effects in high-risk Australian men: development and external validation of a 2-year risk model","volume":"192","author":"Robledo","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026012101523911300_dgaf622-B74","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1210\/clinem\/dgad485","article-title":"Long-term outcomes of testosterone treatment in men: a T4DM postrandomization observational follow-up study","volume":"109","author":"Handelsman","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026012101523911300_dgaf622-B75","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular safety of testosterone-replacement therapy","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"2026012101523911300_dgaf622-B76","doi-asserted-by":"crossref","first-page":"bvaf002","DOI":"10.1210\/jendso\/bvaf002","article-title":"Testosterone replacement therapy and risk of COVID-19 and effect of COVID-19 on testosterone\u2019s treatment effect","volume":"9","author":"Pencina","year":"2025","journal-title":"J Endocr Soc"},{"issue":"3","key":"2026012101523911300_dgaf622-B77","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa2308836","article-title":"Testosterone treatment and fractures in men with hypogonadism","volume":"390","author":"Snyder","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"2026012101523911300_dgaf622-B78","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1056\/NEJMe2313787","article-title":"Breaking news\u2014testosterone treatment and fractures in older men","volume":"390","author":"Grossmann","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"2026012101523911300_dgaf622-B79","doi-asserted-by":"crossref","first-page":"e2348692","DOI":"10.1001\/jamanetworkopen.2023.48692","article-title":"Prostate safety events during testosterone replacement therapy in men with hypogonadism: a randomized clinical trial","volume":"6","author":"Bhasin","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10","key":"2026012101523911300_dgaf622-B80","doi-asserted-by":"crossref","first-page":"e2340030","DOI":"10.1001\/jamanetworkopen.2023.40030","article-title":"Efficacy of testosterone replacement therapy in correcting anemia in men with hypogonadism: a randomized clinical trial","volume":"6","author":"Pencina","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2026012101523911300_dgaf622-B81","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1210\/clinem\/dgad484","article-title":"Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism","volume":"109","author":"Pencina","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026012101523911300_dgaf622-B82","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1210\/clinem\/dgae026","article-title":"Depressive syndromes in men with hypogonadism in the TRAVERSE trial: response to testosterone-replacement therapy","volume":"109","author":"Bhasin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026012101523911300_dgaf622-B83","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamainternmed.2023.7862","article-title":"Effect of testosterone on progression from prediabetes to diabetes in men with hypogonadism: a substudy of the TRAVERSE randomized clinical trial","volume":"184","author":"Bhasin","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"9","key":"2026012101523911300_dgaf622-B84","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"2026012101523911300_dgaf622-B85","doi-asserted-by":"crossref","first-page":"e220223","DOI":"10.1530\/JOE-22-0223","article-title":"Testosterone and type 2 diabetes prevention: translational lessons from the T4DM study","volume":"258","author":"Wittert","year":"2023","journal-title":"J Endocrinol"},{"key":"2026012101523911300_dgaf622-B86","doi-asserted-by":"crossref","first-page":"102611","DOI":"10.1016\/j.eclinm.2024.102611","article-title":"Testosterone and the risk of incident atrial fibrillation in older men: further analysis of the ASPREE study","volume":"72","author":"Tran","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"5","key":"2026012101523911300_dgaf622-B87","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1210\/clinem\/dgac028","article-title":"Relation of testosterone, dihydrotestosterone, and estradiol with changes in outcome measures in the testosterone trials","volume":"107","author":"Stephens-Shields","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026012101523911300_dgaf622-B88","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1517\/14740338.2013.742885","article-title":"Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation","volume":"12","author":"Gur","year":"2013","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"2026012101523911300_dgaf622-B89","doi-asserted-by":"crossref","first-page":"e0200078","DOI":"10.1371\/journal.pone.0200078","article-title":"Cross-sectional and longitudinal determinants of serum sex hormone-binding globulin (SHBG) in a cohort of community-dwelling men","volume":"13","author":"Gyawali","year":"2018","journal-title":"PLoS One"},{"issue":"10","key":"2026012101523911300_dgaf622-B90","doi-asserted-by":"crossref","first-page":"e3536","DOI":"10.1210\/clinem\/dgaf370","article-title":"Debate about the free testosterone hypothesis: useful tool or misguided mirage?","volume":"110","author":"Anawalt","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026012101523911300_dgaf622-B91","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.mce.2009.08.009","article-title":"Interactions of sex hormone-binding globulin with target cells","volume":"316","author":"Rosner","year":"2010","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"2026012101523911300_dgaf622-B92","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.tem.2015.05.001","article-title":"Novel insights in SHBG regulation and clinical implications","volume":"26","author":"Simo","year":"2015","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"2026012101523911300_dgaf622-B93","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1093\/ejendo\/lvae071","article-title":"Testosterone therapy in older men: clinical implications of recent landmark trials","volume":"191","author":"Grossmann","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026012101523911300_dgaf622-B94","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MED.0000000000000886","article-title":"Beyond T-trials, T4DM and TRAVERSE: the next large testosterone randomized controlled trial","volume":"31","author":"Yeap","year":"2024","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"6","key":"2026012101523911300_dgaf622-B95","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40266-025-01209-1","article-title":"Testosterone therapy in older men: present and future considerations","volume":"42","author":"Yeap","year":"2025","journal-title":"Drugs Aging"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf622\/65277214\/dgaf622.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/2\/e339\/65277214\/dgaf622.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/2\/e339\/65277214\/dgaf622.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:53:06Z","timestamp":1768978386000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/2\/e339\/8321888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":95,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,12]]},"published-print":{"date-parts":[[2026,1,21]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf622","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,11,12]]}}}